JNJ-95566692

N/A

Report date: 2026/03/19 17:03:37

Base Information

Drug NameJNJ-95566692

Drug Alias NameJNJ-95566692

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-CD79BAnti-CD20Anti-CD3

TargetsB-cell antigen receptor complex-associated protein beta chainB-lymphocyte antigen CD20T cell surface glycoprotein CD3

Therapy Area/IndicationsLymphoma, Non-Hodgkin

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgiumAustralia

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesJanssen Research & Development Llc

China Registration ClassN/A

Develop Information

Active CompaniesJanssen Research & Development Llc

Inactive CompaniesN/A

Active IndicationsLymphoma, Non-Hodgkin

Inactive IndicationsN/A

Other Information

ATC CodeN/A